Astrazeneca Ab

Marianne Swanson

Peter Guzzo

Sverker Von Unge

Pernilla Sandberg

Kay Brickmann

Patrik Holm

Thomas Elebring

Lanna Li

Robert Andrew Judkins

Anders Broo

Eva-Lotte Lindstedt-Alstermark

Thomas Olsson

Jonas Boström

Christer Ralf Westerlund

Lars Weidolf

Kosrat Amin

Jonas Brånalt

Maria Johansson

Anneli Nordqvist

Anders Holmén

Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R, R, R, R, Rand Rare as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides

The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) &#x3b1; (NR1H3) and/or &#x3b2; (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them. 

Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators

The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) &#x3b1; (NR1H3) and/or &#x3b2; (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

[object Object]

The present invention relates to certain novel compounds of the Formula I to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR)&#x3b1;(NR1H3) and/or &#x3b2;(NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Pyrrole-2,5-dione derivatives as Liver X receptor modulators

Intermediates used in the preparation of compounds of formula I,or a stereoisomer thereof, or a pharmaceutically acceptable form of either selected from the group consisting of a salt, a solvate and a combination thereof,with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S,3R)-(3-amino-2-hydroxybutyl)phosphinic acid.

Aminopropylphosphinic acids

Novel compounds of formula I, with the exception of

(Aminopropyl)methylphosphinic acids

Growing community of inventors

Mölndal, Sweden

Marianne Swanson